Projects
Research Projects (2015, ongoing)
| European Management Platform for children´s interstitial lung diseases (chILD-EU) | Kids lung register |
| In vitro modelling of the surfactant transporter ABCA3 defects | DZL 2.0 |
| Molecular genetic diagnosis of rare pediatric lung diseases | DZL 2.0 |
| HCQ4Surf-E-Rare | Erare, BMBF |
| ENTeR-chILD-COST | EU |
Clinical trials (2015, ongoing)
|
2015- RECRUITING
2015 – ongoing
2015 – ongoing
2016 - ongoing |
Hydroxychloroquine in pediatric ILD: START randomized controlled in parallel-group, then switch placebo to active drug, and STOP randomized controlled in parallel-group to evaluate the efficacy and safety of hydroxychloroquine (HCQ) EudraCT: 2013-003714-40 NCT02615938 A Phase 3, Randomized, Double-Blind,Placebo-Controlled, Crossover Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis,Heterozygous for the F508del-CFTR Mutation, and a Second Allele With a CFTR Mutation Predicted to Have Residual Function Vertex Study Number: VX14-661-108 VX-661 IND Number: 108,105 EudraCT Number: 2014-004788-18. NCT02392234 A Phase 3, Randomized, Double-Blind,Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and OlderWith Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation Vertex Study Number:VX14-661-106, IND Number: 108,105 EudraCT Number: 2014-004837-13, NCT02347657 Phase 3, Open-label, Rollover Study to Evaluate the Safety and Efficacy of Long- term Treatment With VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation Vertex Study Number: VX14-661-110, VX-661 IND Number: 108,105, Ivacaftor IND Number: 74,633 EudraCT Number: 2014-004827-29, 4 NCT02565914 |
|
|
Projects (1999-2015, closed)
| Topic | Funding |
| Großgeräteantrag mit AG Klein; Confokales ZEISS-Lasermikroskop | DFG |
| Chronic tachypnea of infancy; pediatric interstitial lung diseases | DZL 1.0 |
| Israel Kooperationsprojekt on rare lung diseases | Hirmer Stiftung |
| Cells models of the surfactant transporter ABCA3 | DFG-970/8-1 |
| chILD – EU-Projekt: Orphans Unite: chILD better together –? European Management Platform for Childhood Interstitial Lung Diseases. Grant Agreement number 305653 | EU |
| A PHASE 3 EXTENSION STUDY OF ATALUREN (PTC124) IN PATIENTS WITH NONSENSE MUTATION CYSTIC FIBROSIS EudraCT Number 2014-005355-83. NCT02456103 | PTC |
| A Phase 2, Multi-centre Double-Blinded Placebo-Controlled 3 Part Study to evaluate Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of VX661 Monotherapy and VX-661/VX-770 Cotherapy in Subjects with Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation. EudraCT-Nr.: 2011-003821-93. | Vertex |
| A Phase 3, open-label, randomized trial to evaluate the safety and efficacy of MP-376 inhalation solution (AEROQUIN™) versus Tobramycin inhalation solution (TIS) in stable cystic fibrosis patients. EudraCT-Nr.: 2010-019634-26. | MPex |
| An Open-Label, Rollover Study to Evaluate the Long-Term Safety and Efficacy of VX-770 in Subjects with Cystic Fibrosis. EudraCT-Number:2009-012997-1. Dec 2010 – 2013. | Vertex |
| Europäisches Alveolarproteinose-Netzwerk (Eu-PAP-Net) | BMBF |
| A Phase 3, Randomized, Double-Blind, Placebo‑Controlled, Parallel‑Group Study to Evaluate the Efficacy and Safety of VX‑770 in Subjects with Cystic Fibrosis and the G551D Mutation. EudraCT-Number:2008-007416-15. Dec 2009 – Dec 2010. | Vertex |
| A randomized controlled study to investigate the efficacy and safety of 24 weeks of inhaled treatment with glutathione in cystic fibrosis | North American CF foundation (NACF) |
| Deutsches Netzwerk für diffus parenchymatöse Lungenerkrankungen: GOLD.net | BMBF |
| A randomized, double-blind, placebo-controlled parallel group study to investigate the safety and efficacy of two doses of tiotropium bromide (2.5 μg and 5 μg) administered once daily via the Respimat® device for 12 weeks in patients with cystic fibrosis. EudraCT-Number: 2008-001156-43. | Boehringer Ingelheim |
| An exploratory, randomized, double-blind, placebo controlled study to assess the efficacy of multiple doses of omalizumab (Xolair) in cystic fibrosis complicated by allergic bronchopulmonary aspergillosis. EudraCT-Number:2007-006648-23. | Novartis |
| Molekulare Auswirkungen von Gendefekten im Surfactantsyntheseapparat von Typ II Pneumozyten bei interstitiellen Lungenerkrankungen (ILD) | DFG Gr970/7-3 |
| A Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy of 28 Day Oral Administration of AZD9668 in Patients with Cystic Fibrosis. | Astraceneca |
| IGOR-basic – ex vivo study of the effects of inhaled glutathione | Mukoviszidose eV |
| Randomized, placebo-controlled, double-blind study to investigate the efficacy and safety of a 24-week inhalation treatment with glutathione in cystic fibrosis patients | Mukoviszidose eV |
| A Randomised, Open-label, Multicenter, Active controlled study of Tobramycin 100 PARI nebulised with eFlow® versus TOBI® nebulised with PARI LC PLUS® in Cystic Fibrosis Patients. | Pari GmbH |
| International multicentre study in cystic fibrosis (TIP003) | Chiron |
| Pharmacokinetics of inhaled tobramycin | Pari GmbH |
| A mass spectrometric search for serum markers of allergic bronchopulmonary aspergillosis (ABPA) in cystic fibrosis | Mukoviszidose eV |
| Genetik der Collektine bei CF | Mukoviszidose eV |
| Molekulare Auswirkungen von Gendefekten im Surfactantsyntheseapparat von Typ II Pneumozyten bei interstitiellen Lungenerkrankungen (ILD) | DFG Gr970/7-2 |
| Follow up, lung function | Pharmacia |
| A randomized controlled study to investigate the efficacy and safety of 24 weeks of inhaled treatment with glutathione in cystic fibrosis | North American CF foundation (NACF) |
| BI-Trial 543.45: Weltweite, randomisierte Multizenterstudie, Doppel-blind-Placebo-kontrolliert an Patienten mit Cystischer Fibrose | Böhringer Ingelheim |
| Inhaled a1-Antitrypsin in cystic fibrosis | Bayer, Central lab |
| Multicentre, randomized, two arm trial Prolastin® to investigate the optimal deposition site for inhaled Prolastin® in patients with cystic fibrosis | Bayer, Koordinationszentrum |
| AKITA-Deposition of Prolastin in central and peripheral airways | Bayer, Koordinationszentrum |
| Lungenerkrankungen unklarer Ursachen im Neugeborenen- und Kindesalter – biochemische Grundlagen | DFG Gr970/7-1 |
| Oxidative Schädigung bei chronischen respiratorischen Erkrankungen im Kindesalter | DAAD Stipendium |
| Respiratorische Erkrankungen durch gastro-ösophageale Refluxe | Projektförderung von Forschung und Lehre durch die LMU München 2002 |
| Folgestudie – Nachbeobachtung der Kohorte von Kindern und Jugendlichen mit Cystischer Fibrose | Pharmacia 2003/2004 |
| Partizipation an multizenterischer, randomisierter, doppelblinder, plazebokontrollierter Parallelgruppenstudie zur Bewertung der metabolischen und respiratorischen Wirksamkeit von Somatropin bei Kindern und Jugendlichen mit Cystischer Fibrose | Pharmacia 2001/2002 |
| Untersuchung der Surfactant Collectine und der Collectin-kodierenden Gene als potentieller Modifikatoren des Verlaufs der CF-Lungeerkrankung – Deutsch-französisches Gemeinschaftsprojekt | Mukoviszidose eV und der Vaincre la Mucoviscidose 2001 |
| Interaktionen von Surfactant Protein A und D mit Aspergillus fumigatus bei Cystischer Fibrose | Projektförderung von Forschung und Lehre durch die LMU München 2001 |
| Glutathion-Aerosol bei CF | Mukoviszidose eV |
| GSH-Deposition in der Lunge | Cf-Selbsthilfe 2001/2 |
| Chronische Atemtraktinflammation im Säuglings- und Kleinkindalter- nicht-invasive Evaluation der Behandlung mit inhalativen Steroiden | GlaxoWellcome 2001 |
| Bestimmung von Chemokin-Rezeptoren bei Atemwegserkrankungen im Kindesalter | F.-Baur-Stiftung 2000 |
| Untersuchungen der Surfactantdysfunktion mit dem capillären Surfactometer | MMW 2000 |
| Untersuchung allergischer Antikörper gegen rekombinante und natürliche Schimmelpilzallergen wie sie in der Allergie-Diagnostik verwendet werden | Sanofi/Biorad |
| Invasive und nicht-invasive Marker der Atemwegsinflammation | Vaillant-Stiftung |
| Multizenterstudie BEAT, Lavage bei CF | Mukoviszidose e.V. |
| Schlaflabor-Großgeräteantrag, 2 Plätze | DFG/Freistaat Bayern |
| Nicht-invasive Evaluation der Atemwegsinflammation im Kindesalter | F.-Baur-Stiftung 1999 |
| Lung surfactant in Cystic Fibrosis Lung Disease | Mukoviszidose e.V. |
| Surfactantaufnahme und Metabolismus (III) | DFG (Gr 970/3-3) |
| Lungensurfactant und Cystische Fibrose | W. Sander-Stiftung III |
| Multizentrische Studie zur Lavage bei Cystischer Fibrose | Roche |